Sodium Monofluorophosphate (MFP)

What it is

Sodium monofluorophosphate (MFP) is an inorganic salt with the formula Na₂FPO₃. Unlike sodium fluoride (NaF), where fluoride exists as a free F⁻ ion, in MFP the fluorine atom is covalently bonded to phosphorus. This is the structural detail that defines the ingredient's behavior in toothpaste formulations.

Structurally, MFP is a phosphate ion (PO₄³⁻) with one oxygen replaced by fluorine. At the pH of most toothpastes (6.0–7.5), MFP remains intact — it does not release F⁻ immediately. Activation occurs later: the enzyme alkaline phosphatase, present in saliva and dental plaque, hydrolyzes the P–F bond and liberates the fluoride ion at the enamel surface.

Commercial use of MFP began in the 1960s. Its key advantage over NaF at the time was compatibility with chalk-based abrasives: calcium carbonate reacts with free F⁻ ions to form insoluble CaF₂, effectively deactivating the fluoride. MFP, with fluorine in a covalently bound form, avoids this reaction.

How it works

MFP delivers fluoride through a two-step mechanism:

Step 1 — transport. MFP as an intact ion penetrates dental plaque and adsorbs onto hydroxyapatite. The phosphate portion of the molecule shares structural similarity with the phosphate groups in the enamel crystal lattice, promoting specific binding to the tooth surface.

Step 2 — hydrolysis. Alkaline phosphatase in plaque and saliva cleaves the P–F bond. F⁻ is released locally, directly at the enamel surface, after the molecule has already adsorbed — resulting in a locally elevated fluoride concentration.

Once released, F⁻ acts through three established mechanisms:

1. Fluorapatite formation. F⁻ replaces hydroxyl groups (OH⁻) in the hydroxyapatite crystal lattice Ca₁₀(PO₄)₆(OH)₂, forming fluorapatite Ca₁₀(PO₄)₆F₂. This compound has a solubility product 2–3 orders of magnitude lower than hydroxyapatite, making it far more resistant to acid dissolution by cariogenic bacteria.

2. Accelerated remineralization. In the presence of F⁻, calcium and phosphate ions from saliva precipitate more readily onto early carious lesions. Fluoride lowers the energy barrier for crystal nucleation.

3. Inhibition of bacterial acid production. F⁻ inhibits enolase in the glycolytic pathway of S. mutans, reducing lactic acid output. It also interferes with H⁺-ATPase, which bacteria use to maintain intracellular pH under acidic conditions.

Efficacy

Clinical evidence for MFP spans three decades of controlled trials:

Mainwaring & Naylor (1978, PMID 356989) — 3-year double-blind RCT in children. MFP toothpaste produced a statistically significant 20–26% reduction in DMFT increment vs placebo over three years.

Stookey et al. (1988, PMID 3288434) — 3-year RCT comparing 1.14% MFP (1500 ppm F) vs 0.76% MFP (1000 ppm F) in nearly 4,000 children in a nonfluoridated community. The higher concentration showed statistically significant superior caries reduction (20–24% DMFS reduction vs control). Both concentrations outperformed placebo; the higher dose provided an additional measurable benefit.

Stookey & Beiswanger meta-analysis (1993, PMID 8402812) — critical review of 18 head-to-head NaF vs MFP trials. Conclusion: NaF showed a slight but statistically significant advantage of 5–10% over DMFS at equivalent fluoride concentrations. The authors noted this could accumulate to a 10–20% difference over 10–20 years.

Mau et al. (2002, PMID 11763937) — 2-year direct comparison of Colgate MFP vs Crest NaF in children. Result: equivalent anticaries efficacy. The authors attributed this to formulation-level differences compensating for kinetic variation between the two fluoride sources.

The bottom line: MFP in a well-designed formulation delivers anticaries protection comparable to NaF. The historical edge of NaF in meta-analyses partly reflects formulation variables, not the fluoride molecule alone.

Concentration guide

| Concentration | Fluoride (ppm) | Status | |---|---|---| | 0.76% MFP | ~1000 ppm F | Standard OTC minimum | | 1.0% MFP | ~1280 ppm F | Enhanced efficacy | | 1.14% MFP | ~1450 ppm F | Near upper OTC limit | | Below 0.7% | <900 ppm F | Below clinically confirmed threshold |

Safety

MFP is approved by the FDA (21 CFR 355) as an active anticaries agent in OTC toothpastes at concentrations up to 0.76% (1000 ppm F). The EU Cosmetics Regulation (Annex V) permits fluoride-containing dentifrices up to 0.15% F by ion concentration (~1150 ppm F total).

Oral LD50 in rats is approximately 500 mg/kg. A standard 75 mL tube of 0.76% MFP paste contains roughly 570 mg MFP — far below any threshold for adult toxicity during normal use.

As with all fluoride sources, use in children under 6 should be supervised with a pea-sized amount and spitting enforced. Dental fluorosis results from systemic fluoride ingestion during tooth development, not from topical contact with enamel.

Key formulation advantage: MFP is inert in the presence of calcium. Chalk-based abrasives (calcium carbonate, dicalcium phosphate) do not deactivate it, making MFP the preferred fluoride source for calcium abrasive systems.

QDRO position

QDRO formulas use sodium fluoride rather than MFP — the choice reflects a preference for the more extensively studied molecule with the most direct bioavailability. MFP remains a technically sound selection for calcium-abrasive formulas, sensitivity to NaF, or cost-optimized product development.

---

Sources:

• Mainwaring PJ, Naylor MN. (1978). A three-year clinical study to determine the separate and combined caries-inhibiting effects of sodium monofluorophosphate toothpaste and an acidulated phosphate-fluoride gel. Caries Res. PMID: 356989
• Stookey GK et al. (1988). A 3-year clinical trial to compare efficacy of dentifrices containing 1.14% and 0.76% sodium monofluorophosphate. Caries Res. PMID: 3288434
• Stookey GK, Beiswanger BB. (1993). A critical review of the relative anticaries efficacy of sodium fluoride and sodium monofluorophosphate dentifrices. Caries Res. PMID: 8402812
• Volpe AR et al. (1995). The relative anticaries effectiveness of sodium monofluorophosphate and sodium fluoride as contained in currently available dentifrice formulations. Am J Dent. PMID: 7488359
• Mau MS et al. (2002). Comparative anticaries efficacy of sodium fluoride and sodium monofluorophosphate dentifrices. A two-year caries clinical trial. Am J Dent. PMID: 11763937
• Nakashima S et al. (2022). Improved Enamel Acid Resistance by Highly Concentrated Acidulated Phosphate Sodium Monofluorophosphate Solution. Materials (Basel). PMC9610128